𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease

✍ Scribed by Ruth Djaldetti; Rivkah Inzelberg; Nir Giladi; Amos D. Korczyn; Yehudit Peretz-Aharon; Martin J. Rabey; Yuval Herishano; Silvia Honigman; Sami Badarny; Eldad Melamed


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
110 KB
Volume
17
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Levodopa ethylester (LDEE), a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying. We conducted a double‐blind, levodopa‐controlled, multicenter study of oral LDEE solution compared with standard levodopa–carbidopa (LD–CD) tablets. Sixty‐two patients with Parkinson's disease who had “delayed on” and “no‐on” subtypes of response fluctuations were randomly assigned for treatment with LDEE–CD or LD–CD 250/25 mg for 4 weeks (phase A). Only the first morning and first post‐lunch dose of LD were replaced. This was followed by a 2‐week extension with a supplementation of carbidopa (25 mg) to each replaced dose (phase B). Patients filled home diaries 2 weeks before and during the trial period in which times of turning on and off for the two doses were reported. In phase A, mean latency to turning on was reduced by 21% (morning dose) and 17% (post‐lunch dose) in the LDEE–CD group. Percentage of no‐on episodes after the post‐lunch dose was decreased by 21% in the LDEE–CD group but increased by 36% in the LD–CD group (P < 0.01). In phase B, LDEE–CD decreased latencies to on after the morning and post‐lunch doses and no‐on episodes after the post‐lunch dose. The beneficial effects of LDEE were supported by the pharmacokinetic data. Results indicate that LDEE solution is beneficial in ameliorating delayed on and no‐on response fluctuations. This effect of LDEE is due to more rapid levodopa absorption. © 2002 Movement Disorder Society.


📜 SIMILAR VOLUMES


Study of istradefylline in patients with
✍ Robert A. Hauser; Lisa M. Shulman; Joel M. Trugman; John W. Roberts; Akihisa Mor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 1 views

## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A~2A~ receptor a

Early treatment benefits of ropinirole p
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB 👁 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn

Sumanirole versus placebo or ropinirole
✍ Paolo Barone; Janice Lamb; Amanda Ellis; Zoe Clarke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract The aims of this study were to assess the safety, tolerability, and efficacy of sumanirole, a highly selective D~2~ dopamine receptor agonist, versus placebo in subjects with advanced Parkinson's disease (PD), and to demonstrate noninferiority of sumanirole to ropinirole. In this flexib

Randomized trial of tolcapone versus per
✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),